Premium
Calcifediol improves lipid profile in osteopenicatorvastatin‐treated postmenopausal women
Author(s) -
Catalano Antonino,
Morabito Nancy,
Basile Giorgio,
Cucinotta Domenico,
Lasco Antonino
Publication year - 2015
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12390
Subject(s) - medicine , postmenopausal women , physiology
Background Low vitamin D serum levels have been associated with unfavourable lipid profile and poorer response to atorvastatin. Aims of this study were to test the effects of 25‐hydroxyvitamin D 3 (calcifediol) compared to parental vitamin D 3 (cholecalciferol) supplementation on modifications of plasma 25( OH )D levels and lipid profile. Materials and methods Fifty‐seven postmenopausal women (aged 59·03 ± 6·73 years) who were at low risk of fracture and with basal plasma 25( OH )D < 30 ng/mL were included if they were on atorvastatin treatment prescribed as appropriate. Recruited women were randomized to receive oral calcifediol or cholecalciferol, both at a dose of 140 μg according to a weekly regimen. Results At baseline, 25( OH )D was negatively associated with BMI ( r = −0·37; P = 0·004), total cholesterol ( r = −0·31; P = 0·01) and LDL ‐C ( r = −0·32; P = 0·02). After 24 weeks, 25( OH )D increased significantly in both groups ( P < 0·001), although higher levels were obtained with calcifediol as compared with cholecalciferol ( P < 0·001). Only in the calcifediol group, a significant reduction of LDL ‐C ( P = 0·01) and an increase of HDL ‐C ( P = 0·02) were obtained, even after adjustment for age, and baseline BMI , 25( OH )D and lipid levels ( P < 0·05). The percentage changes in 25( OH )D levels were associated with the variations of LDL ‐C ( r = −0·44; P = 0·01) and HDL ‐C levels ( r = 0·30; P = 0·10). Conclusion Calcifediol administration in osteopenic and dyslipidemic postmenopausal women with low 25( OH )D improves lipid profile when added to an ongoing atorvastatin treatment.